BioSight
Companies
Oric Pharmaceuticals, Inc. logo

ORIC

NASDAQSOUTH SAN FRANCISCO, CA
Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals develops small-molecule drug candidates targeting cancer, with two lead programs: rinzimetostat and enozertinib. The company is in the clinical trial stage, advancing these candidates through studies to demonstrate safety and efficacy. Oric is dependent on regulatory approvals and faces typical biotech risks around trial success, manufacturing, and commercialization timelines.

Price history not yet available for ORIC.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar